ScholarIQanswers from OpenAlex
Seagen
FunderResearch funding and supported work
Seagen is a funder indexed in ScholarIQ from OpenAlex.
What is known about Seagen?
ScholarIQrecord summary
American biotechnology company
How many works does Seagen have?
ScholarIQindexed works
Seagen has 2,294 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Seagen?
ScholarIQopenalex
The OpenAlex for Seagen is on the source record.
What are the most-cited papers on Seagen?
ScholarIQmost cited works
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
B.J. Monk, Maria Pilar Barretina-Ginesta, Bhavana Pothuri, Ignace Vergote, Whitney A. Spannuth Graybill, Mansoor Raza Mirza, C. C. McCormick, Domenica Lorusso, Richard G. Moore, Gilles Freyer, Roisin E. O’Cearbhaill, Florian Heitz, David M. O’Malley, Andrés Redondo, Mark S. Shahin, Christof Vulsteke, William H. Bradley, Charlotte Aaquist Haslund, Dana M. Chase, Carmela Pisano, L.L. Holman, M.J. Rubio Pérez, Paul DiSilvestro, Lydia Gaba, Thomas J. Herzog, Ilan Bruchim, Natalie Compton, L. Shtessel, Izabela A. Malinowska, Antonio González-Martı́n
Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy
Felix Carl Saalfeld, Johanna Möller, Petros Christopoulos, Carina Wenzel, Anna Rasokat, Xuefu Wang, Ioannis Vathiotis, David König, Oliver Illini, Christian Grohé, Marcel Wiesweg, Claas Wesseler, Christoph Schubart, Natalie Pelusi, Gernot Rohde, Tobias R. Overbeck, Jutta Kirfel, Jürgen Alt, Diego Kauffmann‐Guerrero, Frank Griesinger, Jonas Kulhavy, Michael Allgäuer, Anna Klimová, Maret Schütz, Daniela E. Aust, Maximilian J. Hochmair, Sacha I. Rothschild, Konstantinos N. Syrigos, Rajwanth Veluswamy, Sebastian Michels, Albrecht Stenzinger, Korinna Jöhrens, Martin Wermke
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Giorgio Valabrega, Bhavana Pothuri, Ana Oaknin, Whitney S. Graybill, Ana Beatriz Sánchez, Colleen McCormick, Jean‐François Baurain, Anna V. Tinker, Hannelore Denys, Roisin E. O’Cearbhaill, Sakari Hietanen, Richard G. Moore, Anja Ør Knudsen, Thibault de La Motte Rouge, Florian Heitz, Tally Levy, Whitney York, Divya Gupta, Bradley J. Monk, Antonio González-Martı́n